| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $910,419 | 11 | 100 |
| Schwendenman Andrew | Chief Accounting Officer | 0 | $0 | 1 | $26,460 | $-26,460 |
| Dhingra Kapil | director | 0 | $0 | 1 | $32,958 | $-32,958 |
| Hill Emily Luisa | Chief Financial Officer | 0 | $0 | 2 | $69,564 | $-69,564 |
| Sarchi Christopher | Chief Commercial Officer | 0 | $0 | 2 | $77,572 | $-77,572 |
| Xynos Konstantinos | Chief Medical Officer | 0 | $0 | 2 | $130,050 | $-130,050 |
| Astley-Sparke Philip | director | 0 | $0 | 1 | $260,169 | $-260,169 |
| Patel Sushil | Chief Executive Officer | 0 | $0 | 2 | $313,646 | $-313,646 |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Over the last 12 months, insiders at Replimune Group, Inc. have bought $0 and sold $910,419 worth of Replimune Group, Inc. stock.
On average, over the past 5 years, insiders at Replimune Group, Inc. have bought $0 and sold $4.84M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,100,000 shares for transaction amount of $14.97M was made by Rhodes Jason P (director) on 2019‑11‑18.
| 2025-12-09 | Sale | Dhingra Kapil | director | 3,169 0.0041% | $10.40 | $32,958 | -22.04% | |
| 2025-12-02 | Sale | Patel Sushil | Chief Executive Officer | 10,000 0.0142% | $11.13 | $111,300 | -19.45% | |
| 2025-11-17 | Sale | Xynos Konstantinos | Chief Medical Officer | 7,248 0.0096% | $9.10 | $65,957 | -4.85% | |
| 2025-11-17 | Sale | Sarchi Christopher | Chief Commercial Officer | 5,208 0.0069% | $9.10 | $47,393 | -4.85% | |
| 2025-08-15 | Sale | Hill Emily Luisa | Chief Financial Officer | 9,154 0.0113% | $5.37 | $49,157 | +39.57% | |
| 2025-05-20 | Sale | Astley-Sparke Philip | director | 32,279 0.0368% | $8.06 | $260,169 | -9.98% | |
| 2025-05-20 | Sale | Patel Sushil | Chief Executive Officer | 25,105 0.0286% | $8.06 | $202,346 | -9.98% | |
| 2025-05-20 | Sale | Xynos Konstantinos | Chief Medical Officer | 7,952 0.0091% | $8.06 | $64,093 | -9.98% | |
| 2025-05-20 | Sale | Hill Emily Luisa | Chief Financial Officer | 2,535 0.0029% | $8.05 | $20,407 | -9.98% | |
| 2025-05-20 | Sale | Sarchi Christopher | Chief Commercial Officer | 3,749 0.0043% | $8.05 | $30,179 | -9.98% | |
| 2025-05-20 | Sale | Schwendenman Andrew | Chief Accounting Officer | 3,287 0.0037% | $8.05 | $26,460 | -9.98% | |
| 2024-12-16 | Sale | Patel Sushil | Chief Executive Officer | 10,000 0.0132% | $12.42 | $124,200 | -25.20% | |
| 2024-11-18 | Sale | Xynos Konstantinos | Chief Medical Officer | 7,246 0.0106% | $10.78 | $78,112 | -12.77% | |
| 2024-11-18 | Sale | Sarchi Christopher | Chief Commercial Officer | 5,207 0.0076% | $10.78 | $56,131 | -12.77% | |
| 2024-08-16 | Sale | Hill Emily Luisa | Chief Financial Officer | 8,938 0.0137% | $10.18 | $90,989 | +8.41% | |
| 2024-06-07 | Sale | Xynos Konstantinos | Chief Medical Officer | 15,881 0.0245% | $7.50 | $119,108 | +36.84% | |
| 2024-05-16 | Sale | Coffin Robert | director | 11,464 0.0189% | $6.47 | $74,172 | +60.79% | |
| 2024-05-16 | Sale | Astley-Sparke Philip | Executive Chairman | 37,928 0.0626% | $6.47 | $245,394 | +60.79% | |
| 2024-05-16 | Sale | Love Colin | Chief Operating Officer | 17,615 0.0291% | $6.47 | $113,969 | +60.79% | |
| 2024-05-16 | Sale | Patel Sushil | Chief Executive Officer | 20,194 0.0333% | $6.47 | $130,655 | +60.79% |
| Astley-Sparke Philip | director | 1405071 1.7016% | $10.34M | 0 | 13 | |
| Patel Sushil | Chief Executive Officer | 333576 0.404% | $2.46M | 0 | 7 | |
| Xynos Konstantinos | Chief Medical Officer | 139685 0.1692% | $1.03M | 0 | 7 | |
| Hill Emily Luisa | Chief Financial Officer | 134368 0.1627% | $988,948.48 | 0 | 3 | |
| Sarchi Christopher | Chief Commercial Officer | 123088 0.1491% | $905,927.68 | 0 | 5 | |
| Schwendenman Andrew | Chief Accounting Officer | 68284 0.0827% | $502,570.24 | 0 | 2 | |
| Dhingra Kapil | director | 0 0% | $0 | 0 | 2 | |
| Omega Fund IV, L.P. | 4763380 5.7687% | $35.06M | 2 | 20 | +27.98% | |
| Slootweg Hugo Alexander | 4721449 5.7179% | $34.75M | 1 | 0 | <0.0001% | |
| Forbion Capital Fund III Cooperatief U.A. | 10 percent owner | 4721449 5.7179% | $34.75M | 1 | 0 | <0.0001% |
| Stampacchia Otello | 4673380 5.6597% | $34.4M | 0 | 1 | ||
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2838968 3.4381% | $20.89M | 1 | 0 | <0.0001% |
| Coffin Robert | director | 1821872 2.2064% | $13.41M | 0 | 15 | |
| Rhodes Jason P | director | 946000 1.1457% | $6.96M | 1 | 11 | +63.12% |
| Love Colin | Chief Operating Officer | 777345 0.9414% | $5.72M | 0 | 22 | |
| Esposito Pamela | Chief Business Officer | 263436 0.319% | $1.94M | 0 | 18 | |
| Lewis Tanya | Chief Dev. Op. Officer | 135293 0.1638% | $995,756.48 | 0 | 3 | |
| Franchi Jean M. | Chief Financial Officer | 128748 0.1559% | $947,585.28 | 0 | 5 | |
| SLATTERY JOSEPH P | director | 6667 0.0081% | $49,069.12 | 1 | 1 | <0.0001% |
$860,541,348 | 82 | -5.10% | $682.13M | |
$1,323,997 | 34 | 0.21% | $570.33M | |
$7,598,498 | 27 | 34.68% | $655.18M | |
$47,612,919 | 22 | -30.91% | $688.48M | |
$46,858,891 | 18 | -11.58% | $626.03M | |
$59,102,045 | 17 | 8.52% | $684.08M | |
$104,137,421 | 15 | 21.28% | $528.73M | |
$26,254,270 | 14 | 24.18% | $705.87M | |
$57,263,116 | 11 | -8.37% | $548.34M | |
$140,543,039 | 10 | 0.77% | $618.97M | |
$75,069,528 | 10 | 19.77% | $605.03M | |
$94,000,000 | 7 | -20.84% | $662.63M | |
$166,385 | 7 | -23.62% | $585.65M | |
Replimune Group, Inc. (REPL) | $49,165,200 | 7 | 12.92% | $607.73M |
$79,246,559 | 5 | -27.73% | $582.77M | |
$51,767,770 | 4 | -41.99% | $608.36M | |
$144,224 | 4 | 21.31% | $555.66M | |
$7,234,370 | 3 | -3.34% | $568.22M | |
$2,857,000 | 2 | -5.23% | $522.76M |
| Increased Positions | 96 | +49.74% | 19M | +22.74% |
| Decreased Positions | 87 | -45.08% | 22M | -26.55% |
| New Positions | 38 | New | 8M | New |
| Sold Out Positions | 37 | Sold Out | 10M | Sold Out |
| Total Postitions | 202 | +4.66% | 80M | -3.81% |
| Baker Bros. Advisors Lp | $98,303.00 | 14.16% | 11.05M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $73,927.00 | 10.65% | 8.31M | -3M | -23.23% | 2025-09-30 |
| Rtw Investments, Lp | $56,922.00 | 8.2% | 6.4M | +4M | +209.72% | 2025-09-30 |
| Blackrock, Inc. | $51,405.00 | 7.41% | 5.78M | +45,514 | +0.79% | 2025-09-30 |
| Fcpm Iii Services B.V. | $37,009.00 | 5.33% | 4.16M | +248,672 | +6.36% | 2025-09-30 |
| Point72 Asset Management, L.P. | $32,306.00 | 4.65% | 3.63M | +3M | +409.43% | 2025-09-30 |
| Vanguard Group Inc | $30,967.00 | 4.46% | 3.48M | +9,707 | +0.28% | 2025-09-30 |
| Tang Capital Management Llc | $30,260.00 | 4.36% | 3.4M | +200,000 | +6.25% | 2025-09-30 |
| State Street Corp | $26,025.00 | 3.75% | 2.92M | +471,437 | +19.22% | 2025-09-30 |
| Braidwell Lp | $24,476.00 | 3.53% | 2.75M | +2M | +550.31% | 2025-09-30 |